Hetlioz vs. Melatonin for the Treatment of Non-24 in Blind People

How the two treatment options compare

Melatonin supplements are well-known for their ability to help you sleep and are considered the standard treatment for non-24-hour sleep-wake disorder (non-24), a circadian rhythm disorder in which a person's body doesn't synchronize with a 24-hour day. This condition commonly affects blind individuals, but not exclusively.

Hetlioz (tasimelteon) is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24). It was approved based on placebo-controlled trials.

Hetlioz, which acts on receptors in the brain for the hormone melatonin, was more effective for treating non-24 than placebo pills. But its effectiveness has not yet been directly compared to taking over-the-counter melatonin.

There have been no clinical research trials that compare the use of Hetlioz and melatonin in a head-to-head fashion. As such, what is "best" largely comes down to which treatment proves more effective for you.

Man sitting on edge of bed in middle of the night

PhotoAlto/Frederic Cirou / Getty Images

Standard Recommendation for Non-24 Treatment

In its last guidelines from 2007, published prior to the availability of Hetlioz, the American Academy of Sleep Medicine (AASM) recommends the use of melatonin for the treatment of non-24. In order to stabilize the genetically determined circadian rhythms that can lead to cycles of insomnia and excessive sleepiness, melatonin can be highly effective.

This stabilization is called entrainment. The rhythms of sleep and wakefulness in blind people can be aligned, or entrained, to the natural day-night patterns. This can be accomplished with very low doses of over-the-counter melatonin (0.3 milligrams, mg).

It is important to select a reputable manufacturer that ensures the quality and precise contents of the product. Many supplement products often contain 3 mg of melatonin (10 times as much as is required for this non-24) or even more. This excessive melatonin may flood the system, counteracting the benefits and potentially leading to side effects.

The timing of the melatonin dose is critical as well. It may be difficult to stabilize the circadian rhythm, and sometimes the condition may recur if a dose is missed. It may require the assistance of a sleep specialist to ensure that the dose amount and timing are appropriate.

Assessing the Treatment Effects

How do you know if the treatment is working? Most people with non-24 experience cycles of insomnia and excessive daytime sleepiness. These symptoms may shift in timing (and intensity) over weeks to months.

This circadian disorder can profoundly impact the ability to function on a regular schedule, affecting work performance, cognitive function (concentration, attention, and short-term memory), and even mood (causing depression, anxiety, or irritability). If treatment is effective, it would be expected that the baseline symptoms should resolve.

Beyond symptomatic improvement, it can be helpful to track the treatment’s effectiveness in other objective ways. Sleep logs and laboratory measurements of circadian phase markers, such as the measurement of melatonin levels in saliva, can be useful.

Importantly, in people with non-24 who are not totally blind, timed light exposure may be a helpful adjunctive therapy. This can be achieved with sunlight exposure or the use of a lightbox. Depending on the nature of the circadian dysfunction, optimal timing of this treatment may vary somewhat. As such, input from a sleep specialist is recommended.

A Word From Verywell

Hopefully, further research will make direct comparisons between Hetlioz and melatonin. This research would give us the best understanding of how effective the medication is. It may also be possible to learn who is the best candidate to use Hetlioz and who may benefit more from melatonin use. In the meanwhile, you may consider discussing the treatment options for non-24 with your board-certified sleep specialist to determine the best option for you.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. National Organization for Rare Disorders. Non-24-Hour Sleep-Wake Disorder.

  2. PR Newswire. FDA Approves HETLIOZ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder. Jan 31, 2014.

  3. Morgenthaler TI, Lee-Chiong T, Allessi C, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders: An American Academy of Sleep Medicine reportSleep. 2007; 30:1445-59. doi:10.1093/sleep/30.11.1445

  4. Lewy AJ, Emens JS, Robert L. Sack, RL, Hasler, BP, Bernert, RA. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian phase. Chronobiology International. 2002; 19:649-658. doi:10.1081/CBI-120004546

  5. Tzischinsky O, Pal I, Epstein, R, Dagan Y, Lavieet, P. The importance of timing in melatonin administration in a blind man. Journal of Pineal Research. 1992; 12:105-108. doi:10.1111/j.1600-079x.1992.tb00035.x